Molecular Partners AG (NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, has announced its participation in two upcoming investor conferences. The management team will engage in fireside chats at: 1) The H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025 at 3:30pm ET, and 2) TD Cowen's 6th Annual Oncology Innovation Summit on May 28, 2025 at 10:00am ET. Both events will be accessible via webcast through the company's website in the investors section.
Molecular Partners AG (NASDAQ: MOLN), una società biotecnologica in fase clinica specializzata in terapie DARPin, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. Il team di gestione parteciperà a discussioni informali in: 1) The H.C. Wainwright 3rd Annual BioConnect Investor Conference al NASDAQ il 20 maggio 2025 alle 15:30 ET, e 2) il 6° Annual Oncology Innovation Summit di TD Cowen il 28 maggio 2025 alle 10:00 ET. Entrambi gli eventi saranno accessibili via webcast tramite il sito web della società nella sezione investitori.
Molecular Partners AG (NASDAQ: MOLN), una empresa biotecnológica en etapa clínica especializada en terapias DARPin, ha anunciado su participación en dos próximas conferencias para inversores. El equipo directivo participará en charlas informales en: 1) The H.C. Wainwright 3rd Annual BioConnect Investor Conference en NASDAQ el 20 de mayo de 2025 a las 3:30 pm ET, y 2) la 6ª Cumbre Anual de Innovación en Oncología de TD Cowen el 28 de mayo de 2025 a las 10:00 am ET. Ambos eventos estarán disponibles vía webcast a través del sitio web de la empresa en la sección de inversores.
Molecular Partners AG(NASDAQ: MOLN)는 DARPin 치료제에 특화된 임상 단계 바이오테크 기업으로, 두 차례의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 경영진은 다음 행사에서 파이어사이드 채팅에 참여합니다: 1) 2025년 5월 20일 오후 3시 30분(동부시간) NASDAQ에서 열리는 H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스, 2) 2025년 5월 28일 오전 10시(동부시간) TD Cowen 제6회 연례 암 혁신 서밋. 두 행사 모두 회사 웹사이트의 투자자 섹션을 통해 웹캐스트로 시청할 수 있습니다.
Molecular Partners AG (NASDAQ : MOLN), une société biotechnologique en phase clinique spécialisée dans les thérapies DARPin, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'équipe de direction participera à des discussions informelles lors de : 1) la 3e conférence annuelle BioConnect Investor de H.C. Wainwright au NASDAQ le 20 mai 2025 à 15h30 ET, et 2) le 6e sommet annuel d'innovation en oncologie de TD Cowen le 28 mai 2025 à 10h00 ET. Les deux événements seront accessibles en webcast via la section investisseurs du site web de la société.
Molecular Partners AG (NASDAQ: MOLN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf DARPin-Therapeutika spezialisiert ist, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Managementteam wird an Fireside-Chats teilnehmen bei: 1) der 3. jährlichen H.C. Wainwright BioConnect Investor Conference an der NASDAQ am 20. Mai 2025 um 15:30 Uhr ET, und 2) dem 6. jährlichen Oncology Innovation Summit von TD Cowen am 28. Mai 2025 um 10:00 Uhr ET. Beide Veranstaltungen sind per Webcast über die Investorenseite der Unternehmenswebsite zugänglich.
Positive
None.
Negative
None.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences.
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ:
Fireside Chat on Tuesday May 20, 2025 beginning at 3:30pm ET
Fireside chat on Wednesday, May 28, 2025 beginning at 10:00am ET
Both events will be webcast and available on the Molecular Partners website, under the investors tab.
About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs
For further details, please contact: Seth Lewis, SVP Investor Relations & Strategy Concord, Massachusetts, U.S. seth.lewis@molecularpartners.com Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Switzerland laura.jeanbart@molecularpartners.com Tel: +41 44 575 19 35
FAQ
When is Molecular Partners (MOLN) presenting at the H.C. Wainwright BioConnect Conference?
Molecular Partners will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20, 2025, at 3:30pm ET.
How can I watch Molecular Partners' (MOLN) presentations at the upcoming investor conferences?
Both presentations will be available via webcast on the Molecular Partners website under the investors tab.
What type of therapeutics does Molecular Partners (MOLN) develop?
Molecular Partners develops a new class of custom-built protein drugs known as DARPin therapeutics.
When is Molecular Partners (MOLN) presenting at TD Cowen's Oncology Innovation Summit?
Molecular Partners will present at TD Cowen's 6th Annual Oncology Innovation Summit on Wednesday, May 28, 2025, at 10:00am ET.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
